Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort
DOI:
https://doi.org/10.2340/actadv.v102.206Keywords:
psoriasis, biologics, PASI, real world evidence, effectiveness, observational studiesAbstract
Real-world evidence, directly comparing the effectiveness of interleukin (IL)17-inhibitors, IL23-inhibitors, tumour necrosis factor alpha (TNF-α)-inhibitors and an IL12/23-inhibitor in psoriasis, is scarce. The aim of this study was to directly compare the first-year effectiveness of biologic therapies for psoriasis, corrected for confounders. This prospective, multicentre cohort study assessed BioCAPTURE data on etanercept, adalimumab, ustekinumab, secukinumab, ixekizumab, and guselkumab in 1,080 treatment episodes of 700 patients with psoriasis. The course of the mean absolute Psoriasis Area and Severity Index (PASI) and the proportion of patients who achieved PASI90/PASI75 were compared using linear mixed models and mixed logistic regression models respectively, corrected for baseline PASI, biologic naivety, and weight. Patients treated with adalimumab, ustekinumab, secukinumab, ixekizumab, or guselkumab all had a significantly lower mean PASI after 12 months compared with etanercept, and significantly higher overall odds of reaching PASI90 than those treated with etanercept. Patients treated with ixekizumab or guselkumab also had higher probabilities of reaching PASI90 than adalimumab, ustekinumab, and secukinumab. Relative to randomized controlled trials, the proportions of patients who reached PASI90/75 were lower in this real-world study.
Downloads
References
Bai F, Li GG, Liu Q, Niu X, Li R, Ma H. Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials. J Immunol Res 2019; 2019: 2546161.
https://doi.org/10.1155/2019/2546161 DOI: https://doi.org/10.1155/2019/2546161
Jabbar-Lopez ZK, Yiu ZZN, Ward V, Exton LS, Mohd Mustapa MF, Samarasekera E, et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol 2017; 137: 1646-1654.
https://doi.org/10.1016/j.jid.2017.04.009 DOI: https://doi.org/10.1016/j.jid.2017.04.009
Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA. Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. J Am Acad Dermatol 2018; 79: 135-144.e7.
https://doi.org/10.1016/j.jaad.2018.02.027 DOI: https://doi.org/10.1016/j.jaad.2018.02.027
Sawyer LM, Malottki K, Sabry-Grant C, Yasmeen N, Wright E, Sohrt A, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. PLoS ONE 2019; 14: e0220868.
https://doi.org/10.1371/journal.pone.0220868 DOI: https://doi.org/10.1371/journal.pone.0220868
Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Daudén E, Sánchez-Carazo JL, et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol 2012; 148: 463-470.
https://doi.org/10.1001/archdermatol.2011.2768 DOI: https://doi.org/10.1001/archdermatol.2011.2768
Zweegers J, Groenewoud JMM, van den Reek J, Otero ME, van de Kerkhof PCM, Driessen RJB, et al. Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry. Br J Dermatol 2017; 176: 1001-1009.
https://doi.org/10.1111/bjd.15023 DOI: https://doi.org/10.1111/bjd.15023
Strober BE, Bissonnette R, Fiorentino D, Kimball AB, Naldi L, Shear NH, et al. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). J Am Acad Dermatol 2016; 74: 851-861.e4.
https://doi.org/10.1016/j.jaad.2015.12.017 DOI: https://doi.org/10.1016/j.jaad.2015.12.017
Carrera CG, Dapavo P, Malagoli P, Naldi L, Arancio L, Gaiani F, et al. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis. J Dermatolog Treat 2018; 29: 481-486.
https://doi.org/10.1080/09546634.2017.1395805 DOI: https://doi.org/10.1080/09546634.2017.1395805
Tada Y, Watanabe R, Noma H, Kanai Y, Nomura T, Kaneko K. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. J Dermatol Sci 2020; 99: 53-61.
https://doi.org/10.1016/j.jdermsci.2020.06.003 DOI: https://doi.org/10.1016/j.jdermsci.2020.06.003
Cinelli E, Fabbrocini G, Megna M. Real-world experience versus clinical trials: pros and cons in psoriasis therapy evaluation. Int J Dermatol 2022; 61: e107-e108.
https://doi.org/10.1111/ijd.15644 DOI: https://doi.org/10.1111/ijd.15644
West BT. Analyzing longitudinal data with the linear mixed models procedure in SPSS. Eval Health Prof 2009; 32: 207-228.
https://doi.org/10.1177/0163278709338554 DOI: https://doi.org/10.1177/0163278709338554
van Lümig PPM, Driessen RJB, Kievit W, Boezeman JBM, van de Kerkhof PCM, de Jong EMGJ. Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice. J Am Acad Dermatol 2013; 68: 57-63.
https://doi.org/10.1016/j.jaad.2012.05.040 DOI: https://doi.org/10.1016/j.jaad.2012.05.040
Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2020; 1: Cd011535.
https://doi.org/10.1002/14651858.CD011535.pub3 DOI: https://doi.org/10.1002/14651858.CD011535.pub3
Xu S, Gao X, Deng J, Yang J, Pan F. Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis. J Dtsch Dermatol Ges 2021; 19: 47-56.
https://doi.org/10.1111/ddg.14308 DOI: https://doi.org/10.1111/ddg.14308
Ohata C, Ohyama B, Katayama E, Nakama T. Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: a single-center experience. J Dermatol 2020; 47: 405-408.
https://doi.org/10.1111/1346-8138.15247 DOI: https://doi.org/10.1111/1346-8138.15247
Richter L, Vujic I, Sesti A, Monshi B, Sanlorenzo M, Posch C, et al. Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria. J Dtsch Dermatol Ges 2017; 15: 309-317.
https://doi.org/10.1111/ddg.13191 DOI: https://doi.org/10.1111/ddg.13191
Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, et al. Randomized trial replication using observational data for comparative effectiveness of secukinumab and ustekinumab in psoriasis: a study from the British Association of Dermatologists Biologics and Immunomodulators Register. JAMA Dermatol 2021; 157: 66-73.
https://doi.org/10.1001/jamadermatol.2020.4202 DOI: https://doi.org/10.1001/jamadermatol.2020.4202
Herrera-Acosta E, Garriga-Martina GG, Suárez-Pérez JA, Martínez-García EA, Herrera-Ceballos E. Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: real-world practice. Dermatol Ther 2020; 33: e13313.
https://doi.org/10.1111/dth.13313 DOI: https://doi.org/10.1111/dth.13313
Ruggiero A, Fabbrocini G, Cinelli E, Megna M. Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison. J Am Acad Dermatol 2021; 85: 1028-1030.
https://doi.org/10.1016/j.jaad.2021.01.025 DOI: https://doi.org/10.1016/j.jaad.2021.01.025
Chiricozzi A, Balato A, Conrad C, Conti A, Dapavo P, Ferreira P, et al. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. J Dermatolog Treat 2020; 31: 476-483.
https://doi.org/10.1080/09546634.2019.1671577 DOI: https://doi.org/10.1080/09546634.2019.1671577
Galluzzo M, Caldarola G, De Simone C, Bernardini N, Moretta G, Pallotta S, et al. Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy. Expert Opin Biol Ther 2021; 21: 1299-1310.
https://doi.org/10.1080/14712598.2021.1941862 DOI: https://doi.org/10.1080/14712598.2021.1941862
Deza G, Notario J, Lopez-Ferrer A, Vilarrasa E, Ferran M, Del Alcazar E, et al. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad Dermatol Venereol 2019; 33: 553-559.
https://doi.org/10.1111/jdv.15288 DOI: https://doi.org/10.1111/jdv.15288
Drerup KA, Seemann C, Gerdes S, Mrowietz U. Effective and safe treatment of psoriatic disease with the anti-IL-23p19 biologic tildrakizumab: results of a real-world prospective cohort study in nonselected patients. Dermatology 2021 Nov 12 [Epub ahead of print].
https://doi.org/10.1159/000519924 DOI: https://doi.org/10.1159/000519924
Ruggiero A, Fabbrocini G, Cinelli E, Megna M. Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: a real-life 52-week retrospective study. Dermatol Ther 2021; 34: e14673.
https://doi.org/10.1111/dth.14673 DOI: https://doi.org/10.1111/dth.14673
Rivera R, Velasco M, Vidal D, Carrascosa JM, Daudén E, Vilarrasa E, et al. The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: a Spanish multicentre retrospective study. Dermatol Ther 2020; 33: e14066.
https://doi.org/10.1111/dth.14066 DOI: https://doi.org/10.1111/dth.14066
Schwarz CW, Loft N, Rasmussen MK, Nissen CV, Dam TN, Ajgeiy KK, et al. Predictors of response to biologics in patients with moderate-to-severe psoriasis: a Danish nationwide cohort study. Acta Derm Venereol 2021; 101: adv00579.
https://doi.org/10.2340/actadv.v101.351 DOI: https://doi.org/10.2340/actadv.v101.351
Egeberg A, Ottosen MB, Gniadecki R, Broesby-Olsen S, Dam TN, Bryld LE, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol 2018; 178: 509-519.
https://doi.org/10.1111/bjd.16102 DOI: https://doi.org/10.1111/bjd.16102
Colombo D, Bianchi L, Fabbrocini G, Corrao S, Offidani A, Stingeni L, et al. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study. Dermatol Ther 2022; 35: e15166.
https://doi.org/10.1111/dth.15166 DOI: https://doi.org/10.1111/dth.15166
Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsley R, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol 2020; 182: 1158-1166.
https://doi.org/10.1111/bjd.18333 DOI: https://doi.org/10.1111/bjd.18333
Kemény L, Berggren L, Dossenbach M, Dutronc Y, Paul C. Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3. J Dermatolog Treat 2019; 30: 19-26.
https://doi.org/10.1080/09546634.2018.1473551 DOI: https://doi.org/10.1080/09546634.2018.1473551
Bissonnette R, Luger T, Thaçi D, Toth D, Messina I, You R, et al. Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. Br J Dermatol 2017; 177: 1033-1042.
https://doi.org/10.1111/bjd.15706 DOI: https://doi.org/10.1111/bjd.15706
Paul C, Griffiths CEM, van de Kerkhof PCM, Puig L, Dutronc Y, Henneges C, et al. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: results from IXORA-S, a phase 3 study. J Am Acad Dermatol 2019; 80: 70-79.e3.
https://doi.org/10.1016/j.jaad.2018.06.039 DOI: https://doi.org/10.1016/j.jaad.2018.06.039
Additional Files
Published
How to Cite
License
Copyright (c) 2022 Marloes E. van Muijen, Sarah E. Thomas, Hans M.M. Groenewoud, Marisol E. Otero, Paul M. Ossenkoppele, Marcellus D. Njoo, Sharon R.P. Dodemont, Else N. Kop, Maartje A.M. Berends, Marjolein I.A. Koetsier, Johannes M. Mommers, John E.M. Körver, Ron A. Tupker, Marjolein S. de Bruin-Weller, Lizelotte J.M.T. Weppner-Parren, Bas Peters, Marloes M. Kleinpenning, Astrid L.A. Kuijpers, W. Peter Arnold, Paula P.M. van Lümig, Juul M.P.A. van den Reek, Elke M.G.J. de Jong
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
